Hengrui Pharma targets obesity drug launch after test success
The Chinese drug company is looking to break into the big league for weight-loss treatments after its injection demonstrated sustained weight loss in Phase Three trials Key Takeaways: Participants receiving…
PomDoc offers up well-conceived but overvalued digital healthcare IPO
The online health services provider aims to raise up to $30 million through a Nasdaq listing, even as its liabilities far outweigh its assets Key Takeaways: PomDoc aims to raise…
Fortune smiles again on WuXi AppTec with profit surge
The drug services giant has forecast a jump in revenue for the first half and a doubling of net profit, after U.S. policy concerns abated Key Takeaways: The projected results…
Private healthcare’s unclear road, and a surging cosmetic surgeon
Private clinic operators for medical treatments like eye and dental care are facing a difficult path as Chinese consumers rein in their spending. What's ahead for this group? And cosmetic surgery services provider So-Young's shares have soared in recent weeks as investors embrace its shifting business model. Why are they suddenly so confident?
RemeGen’s $4.2 billion licensing deal falls flat with investors
The biopharma firm had fanned excitement over a rights deal for its autoimmune drug but the eventual terms, with just a small portion of upfront cash, left the market disappointed…
HBM notches up another mega deal but is the model sustainable?
The biotech has agreed to sell rights to one of its cancer drugs under development for up to $670 million, adding more fuel to its share price rebound this year…
Chaoju Eye Care preparing to re-enter acquisition mode?
The private hospital and clinic operator announced two new purchases, signaling a potential return to acquisitions after a quiet period last year Key Takeaways: Chaoju Eye Care announced plans to…
Recent Articles
RELATED ARTICLES
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK -
Medtide launches IPO to bulk up its weight-loss business
3880.HK
-
3SBio hits the big time with $6 billion cancer drug deal
1530.HK
- RNA drug developer Ribo Life targets fresh funding channel
-
CSPC Pharma teases big bucks deals after earnings miss
1093.HK
- Will Trump’s drug order put the brakes on China’s overseas pharma drive?
-
BRIEF: Hengrui Pharma surges in trading debut for $1.25 billion IPO
1276.HK 600276.SHG
